Business

Cramer’s lightning round: I think Chegg is a buy here

Products You May Like

Matterport: “3D camera, everybody loves 3D. I’ve never made any money on 3D. I’m going to have to take a big pass since that’s stock already moved too much.”

Oscar Health: “Oh geez. No. Sometimes you need what I call a raison d’être … and I see no raison d’être for this health insurance company. We’ve got enough health insurance companies. We’ve got all we need. I know that sounds callous, but we don’t need these guys. Sorry.”

Lemonade: “You know, it’s a good company. I should say this about Oscar too. These are good companies. Oscar’s got great data. Lemonade has got some terrific pricing, but that doesn’t make for a great stock, and that’s the problem. Oscar is a great company, not a great stock. Lemonade is a great company, not a great stock. I teach in this [CNBC Investing Club] that there’s a difference, and most people don’t seem to know the difference, so we have to teach.”

BioNano Genomics: “There’s not much there, and you know what, it’s a good spec. I actually like [CRISPR Therapeutics]. I do. I’m not against the genomics. I like CRISPR.”

Bristol Myers Squibb: “My charitable trust sold it about 10 points ago, and the reason we did was we just didn’t say, I don’t want to say excitement. That’s wrong. But we just didn’t see enough to merit that investment over others we felt in the drug group. I felt it when it was at 2.8% [dividend yield]. At 3.59%, I’m with you, sir. … You don’t want to sell Bristol at 3.59% yield.”

Chegg: “I’m going to go out on a limb … I think Chegg is actually a buy here, OK? I think it’s come down enough.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]

Products You May Like

Articles You May Like

Goldman Sachs: Why individual investors need to look at private investments to further grow wealth
Demand for Roth IRA conversions may increase — even without tax hikes from President-elect Donald Trump
Rocket Lab stock pops 25% after company reports strong revenue growth, first Neutron deal
Spain’s Poorly Designed Tax Policy Hurts Its Competitiveness
Fed’s Kashkari says Trump tariffs could reheat inflation if they provoke global trade ‘tit for tat’

Leave a Reply

Your email address will not be published. Required fields are marked *